Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:CRVS 21 January 2026

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
21 January 2026
···
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals shares soared over 167% to $21.41 in after-hours trading Tuesday after reporting positive placebo-controlled trial results for its experimental eczema pill. The company launched a $150 million underwritten stock and warrant offering following the data release. Analysts raised price targets. About 84 million shares changed hands.
21 January 2026
··

Stock Market Today

  • GE Aerospace vs. Textron: Evaluating Aerospace & Defense Stock Prospects
    March 20, 2026, 1:12 PM EDT. GE Aerospace and Textron Inc. are key competitors in the aerospace and defense industry, benefiting from rising air traffic and expanding U.S. defense budgets. GE Aerospace's strength lies in its engine platforms like LEAP, GEnx, and GE9X, securing over 500 engine wins at the 2025 Dubai Airshow and a $5 billion U.S. Air Force contract for F110 engines. The company plans substantial investments exceeding $2 billion by 2026 in MRO (Maintenance, Repair, and Overhaul) and manufacturing facilities. GE also increased dividends and authorized a $20 billion share buyback. Textron's Aviation unit saw 16.2% revenue growth in 2025 fueled by commercial air travel's recovery. Both firms face growth opportunities but differ in scale and strategic focus. Investors should weigh GE's broad engine portfolio and defense contracts against Textron's aviation segment momentum.
Go toTop